252 related articles for article (PubMed ID: 27567889)
1. Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.
Rayess N; Rahimy E; Ying GS; Pefkianaki M; Franklin J; Regillo CD; Ho AC; Hsu J
Am J Ophthalmol; 2016 Nov; 171():47-52. PubMed ID: 27567889
[TBL] [Abstract][Full Text] [Related]
2. Enhanced depth imaging optical coherence tomography of the choroid in central retinal vein occlusion.
Tsuiki E; Suzuma K; Ueki R; Maekawa Y; Kitaoka T
Am J Ophthalmol; 2013 Sep; 156(3):543-547.e1. PubMed ID: 23688711
[TBL] [Abstract][Full Text] [Related]
3. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Kim H; Lee SC; Kwon KY; Lee JH; Koh HJ; Byeon SH; Kim SS; Kim M; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1497-1503. PubMed ID: 26626772
[TBL] [Abstract][Full Text] [Related]
4. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J
Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
[TBL] [Abstract][Full Text] [Related]
5. Baseline choroidal thickness as a short-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion.
Rayess N; Rahimy E; Ying GS; Pefkianaki M; Franklin J; Regillo CD; Ho AC; Hsu J
Br J Ophthalmol; 2019 Jan; 103(1):55-59. PubMed ID: 29567791
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.
Light JG; Tian J; Wenick AS
Ophthalmol Retina; 2021 Sep; 5(9):888-900. PubMed ID: 33227561
[TBL] [Abstract][Full Text] [Related]
7. Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
Chen AX; Greenlee TE; Conti TF; Briskin IN; Singh RP
Ophthalmol Retina; 2020 Dec; 4(12):1158-1169. PubMed ID: 32480014
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma.
Lee EK; Yu HG
Korean J Ophthalmol; 2019 Jun; 33(3):228-237. PubMed ID: 31179654
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
11. QUALITATIVE AND QUANTITATIVE FOLLOW-UP USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF RETINAL VEIN OCCLUSION TREATED WITH ANTI-VEGF: Optical Coherence Tomography Angiography Follow-up of Retinal Vein Occlusion.
Sellam A; Glacet-Bernard A; Coscas F; Miere A; Coscas G; Souied EH
Retina; 2017 Jun; 37(6):1176-1184. PubMed ID: 27685676
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
[TBL] [Abstract][Full Text] [Related]
13. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
15. CLINICAL FINDINGS OF EYES WITH MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION REFRACTORY TO RANIBIZUMAB.
Hasegawa T; Kawano T; Maruko I; Koizumi H; Iida T
Retina; 2018 Jul; 38(7):1347-1353. PubMed ID: 28492435
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.
Kida T; Osuka S; Fukumoto M; Sato T; Harino S; Oku H; Ikeda T
Ophthalmologica; 2020; 243(2):102-109. PubMed ID: 31851998
[TBL] [Abstract][Full Text] [Related]
17. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
Campos A; Campos EJ; do Carmo A; PatrÃcio M; Castro de Sousa JP; Ambrósio AF; Silva R
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
[TBL] [Abstract][Full Text] [Related]
18. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
Chatziralli I; Theodossiadis G; Parikakis E; Mitropoulos PG; Theodossiadis P
Ophthalmic Res; 2017; 58(4):203-208. PubMed ID: 28427057
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.
Januschowski K; Feltgen N; Pielen A; Spitzer B; Rehak M; Spital G; Dimopoulos S; ; Meyer CH; Szurman GB
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):457-462. PubMed ID: 27632214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
